ProKidney Corp. (NASDAQ:PROK - Get Free Report) SVP Darin J. Weber sold 16,438 shares of the business's stock in a transaction on Monday, April 22nd. The shares were sold at an average price of $2.51, for a total transaction of $41,259.38. Following the transaction, the senior vice president now directly owns 155,194 shares of the company's stock, valued at approximately $389,536.94. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
ProKidney Stock Performance
Shares of PROK opened at $2.53 on Wednesday. ProKidney Corp. has a 1 year low of $1.12 and a 1 year high of $13.51. The firm has a fifty day moving average of $1.63 and a 200-day moving average of $1.74. The company has a market cap of $580.24 million, a price-to-earnings ratio of -4.44 and a beta of 1.08.
ProKidney (NASDAQ:PROK - Get Free Report) last issued its quarterly earnings data on Thursday, March 21st. The company reported ($0.09) earnings per share for the quarter, beating analysts' consensus estimates of ($0.19) by $0.10. Analysts predict that ProKidney Corp. will post -0.65 EPS for the current year.
Institutional Investors Weigh In On ProKidney
The Gold Grab of the Century
From Colonial Metals | Ad
When central banks buy gold…
The rich buy right along with them.
And central banks are buying at breakneck pace.
Last year… 1,037 tons.
Just 45 tons less than the record set two years ago.
That's why we have released our Free Precious Metals Investment Guide.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Jump Financial LLC bought a new stake in shares of ProKidney during the third quarter valued at about $216,000. SG Americas Securities LLC bought a new stake in shares of ProKidney during the third quarter valued at about $78,000. Finally, Federated Hermes Inc. raised its stake in shares of ProKidney by 10,984.7% during the fourth quarter. Federated Hermes Inc. now owns 113,286 shares of the company's stock valued at $202,000 after purchasing an additional 112,264 shares in the last quarter. 51.59% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
Several equities analysts have recently issued reports on PROK shares. Bank of America downgraded shares of ProKidney from a "buy" rating to a "neutral" rating in a report on Tuesday, January 2nd. Morgan Stanley started coverage on shares of ProKidney in a report on Thursday, March 7th. They set an "equal weight" rating and a $3.00 price target for the company.
Check Out Our Latest Research Report on PROK
About ProKidney
(
Get Free Report)
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
